[
    [
        {
            "time": "2018-01-03",
            "original_text": "Top 5 Biotech Stocks for 2018",
            "features": {
                "keywords": [
                    "biotech",
                    "stocks",
                    "2018"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Top 5 Biotech Stocks for 2018",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 3,
                "Headline_Structure": 8,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors",
            "features": {
                "keywords": [
                    "Gilead",
                    "HiFiBiO",
                    "T-Cell",
                    "Receptors"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Cramer's lightning round: The sweet spot for buying shares of Clorox",
            "features": {
                "keywords": [
                    "Cramer",
                    "Clorox",
                    "buying",
                    "shares"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "consumer goods"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Cramer's lightning round: The sweet spot for buying shares of Clorox",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "Noteworthy Wednesday Option Activity: FIT, ROST, ABBV",
            "features": {
                "keywords": [
                    "option activity",
                    "FIT",
                    "ROST",
                    "ABBV"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "retail"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Noteworthy Wednesday Option Activity: FIT, ROST, ABBV",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-07",
            "original_text": "Here's Why J&J (JNJ) is a Good Bet in a Troubled Market",
            "features": {
                "keywords": [
                    "JNJ",
                    "troubled market",
                    "good bet"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Here's Why J&J (JNJ) is a Good Bet in a Troubled Market",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-08",
            "original_text": "Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again",
            "features": {
                "keywords": [
                    "AbbVie",
                    "earnings estimates",
                    "poised"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-09",
            "original_text": "Merck & Other Pharma Players Await FDA Decisions in October",
            "features": {
                "keywords": [
                    "Merck",
                    "FDA",
                    "decisions",
                    "pharma"
                ],
                "sentiment_score": 0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharma"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Merck & Other Pharma Players Await FDA Decisions in October",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-10",
            "original_text": "Here's Why J&J (JNJ) is a Good Bet in a Troubled Market",
            "features": {
                "keywords": [
                    "JNJ",
                    "troubled market",
                    "good bet"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Here's Why J&J (JNJ) is a Good Bet in a Troubled Market",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-11",
            "original_text": "Mylan’s Humira Biosimilar Opportunity in Europe",
            "features": {
                "keywords": [
                    "Mylan",
                    "Humira",
                    "biosimilar",
                    "Europe"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Mylan’s Humira Biosimilar Opportunity in Europe",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-12",
            "original_text": "The hidden dangers of testosterone replacement therapy you should know about",
            "features": {
                "keywords": [
                    "testosterone",
                    "replacement",
                    "therapy",
                    "dangers"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharma"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "The hidden dangers of testosterone replacement therapy you should know about",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-01-13",
            "original_text": "Nobel Recognizes Science Leading to AbbVie's Top-Selling Drug",
            "features": {
                "keywords": [
                    "Nobel",
                    "science",
                    "AbbVie",
                    "top-selling drug"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Nobel Recognizes Science Leading to AbbVie's Top-Selling Drug",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]